Cognition Therapeutics CEO Issues Letter to Shareholders
Cognition Therapeutics, Inc. (CGTX)
Company Research
Source: GlobeNewswire
Advancing Zervimesine (CT1812) towards late-stage trials for dementia with Lewy bodies (DLB) psychosis Fully funded $80 million Phase 2 START trial readout expected in the second half of 2027 PURCHASE, N.Y., March 31, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage neuroscience company developing drugs that treat neurodegenerative disorders, has published CEO Lisa Ricciardi’s Letter to Shareholders. The full text of the letter follows. A MESSAGE FROM OUR CHIEF EXECUTIVE OFFICER To my fellow Shareholders, We made significant progress in 2025 towards our goal of developing transformative treatments for neurodegenerative diseases. As discussed on our financial results conference call last week, we are advancing zervimesine (CT1812) in late-stage trials for the treatment of the DLB psychosis. And in parallel we are making good progress in our START trial in mild cognitive impairment (MCI) and early Alzheimer’s disease. Compelling SHIMMER Resu
Show less
Read more
Impact Snapshot
Event Time:
CGTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CGTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CGTX alerts
High impacting Cognition Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CGTX
News
- Cognition Therapeutics CEO Issues Letter to Shareholders [Yahoo! Finance]Yahoo! Finance
- Cognition Therapeutics (CGTX) had its "buy" rating reaffirmed by Chardan Capital. They now have a $4.00 price target on the stock.MarketBeat
- Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development UpdateGlobeNewswire
- Cognition Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results [Yahoo! Finance]Yahoo! Finance
- Cognition Therapeutics to Report Fourth Quarter and Year End 2025 Financial ResultsGlobeNewswire
CGTX
Earnings
- 5/7/25 - Miss
CGTX
Sec Filings
- 3/26/26 - Form S-8
- 3/26/26 - Form 10-K
- 3/26/26 - Form 8-K
- CGTX's page on the SEC website